News Release

Printer Friendly Version View printer-friendly version << Back
February 18, 2009 at 8:02 AM EST

Quidel Corporation Webinar Addresses Management of Influenza in Long-Term Care Facilities

SAN DIEGO--(BUSINESS WIRE)--Feb. 18, 2009-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today the sponsorship of a live webinar: Rapid Recognition and Management of Influenza Outbreaks in Long-term Care Facilities (LTCFs). The live webinar takes place tomorrow, February 19, 2009 from 11:30 a.m. to 12:30 p.m. PST. To register, go to: www.quidel.com/webinars.

The webinar will include a presentation given by Dominic Dwyer, M.D., prominent medical virologist and infectious disease physician at Westmead Hospital in Sydney, Australia. The presentation will be followed by a question and answer session. Dr. Dwyer will discuss the need for early recognition and response to influenza outbreaks and the importance of surveillance, rapid diagnosis and antiviral medications in controlling outbreaks within LTCFs. He will also discuss how participants can respond more quickly to an influenza outbreak with early recognition and determine the best course of treatment for patients with timely diagnoses.

Dr. Dwyer has a clinical and research interest in viral diseases of public health importance, including influenza, HIV and arboviruses. He has assisted regional and international organizations in outbreak investigations and has just completed a major three-year study on respiratory virus outbreaks in aged-care facilities, including interventions that can prevent disease transmission.

“Quidel is pleased to sponsor this webinar designed to increase awareness of point-of-care testing and management of patients with viral illnesses that can spread rapidly,” said Caren Mason, president and CEO of Quidel. “As patients in long-term care facilities are often more susceptible to infectious diseases due to weaker immune systems and close contact, early detection through products like Quidel’s QuickVue® Influenza A+B test are important for positive medical decision-making. We are also proud of our involvement, as the esteemed virologist Dr. Dwyer will be sharing his knowledge on the management of diseases that impact public heath -- a topic that is timely and of great consequence in our society.”

For more information regarding this webinar, or to obtain the archived presentation, visit www.quidel.com/webinars or email Quidel at webinars@quidel.com.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue®, Quidel’s portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel'sSpecialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.flutest.com, www.quidel.com, or www.colorectal-test.com.

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the timing of onset, length and severity of cold and flu seasons, the level of success in executing our strategic initiatives, uncertainty surrounding the detection of novel influenza viruses involving human specimens, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors and the level of success in our recent distributor incentive programs, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration, intellectual property, product liability, environmental or other litigation, required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower-than-anticipated sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Source: Quidel Corporation

Quidel Corporation
John Radak, Chief Financial Officer
Porter Novelli Life Sciences
Shirley Chow, 212-601-8308